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Abstract: Pituitary neuroendocrine tumors (PitNETs) constitute approximately 15% of all brain 
tumors, and most have a sporadic origin. Recent studies suggest that altered alternative splicing 
and, consequently, appearance of aberrant splicing variants, is a common feature of most tumor 
pathologies. Moreover, spliceosome is considered an attractive therapeutic target in tumor 
pathologies, and the inhibition of SF3B1 (e.g., using pladienolide-B) has been shown to exert 
antitumor effects. Therefore, we aimed to analyze the expression levels of selected splicing-
machinery components in 261 PitNETs (somatotropinomas/non-functioning 
PitNETS/corticotropinomas/prolactinomas) and evaluated the direct effects of pladienolide-B in 
cell proliferation/viability/hormone secretion in human PitNETs cell cultures and pituitary cell 
lines (AtT-20/GH3). Results revealed a severe dysregulation of splicing-machinery components in 
all the PitNET subtypes compared to normal pituitaries and a unique fingerprint of splicing-
machinery components that accurately discriminate between normal and tumor tissue in each 
PitNET subtype. Moreover, expression of specific components was associated with key clinical 
parameters. Interestingly, certain components were commonly dysregulated throughout all 
PitNET subtypes. Finally, pladienolide-B reduced cell proliferation/viability/hormone secretion in 
PitNET cell cultures and cell lines. Altogether, our data demonstrate a drastic dysregulation of the 
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splicing-machinery in PitNETs that might be associated to their tumorigenesis, paving the way to 
explore the use of specific splicing-machinery components as novel diagnostic/prognostic and 
therapeutic targets in PitNETs. 
Keywords: splicing; spliceosome; pituitary neuroendocrine tumors; pladienolide-B. 
 
1. Introduction 
Pituitary neuroendocrine tumors (PitNETs), formerly referred to as pituitary adenomas, are 
more abundant than often thought, as they represent approximately 15% of all brain tumors and 
have an estimated prevalence that ranges from 1 in 865–2688 people [1,2]. Likewise, PitNETs have 
been classically considered as a benign pathology because they rarely metastasize, thus they were 
termed adenomas. However, the great variety of clinical behaviors accompanying these patholo-
gies, coupled to their diverse and severe associated comorbidities and increased mortality, led the 
“International Pituitary Pathology Club” to propose, in a recent consensus, a reclassification of pitu-
itary tumors and to establish the nomenclature of “pituitary neuroendocrine tumors (PitNETs)” 
instead of “pituitary adenomas” [3].  
Interestingly, the vast majority of PitNETs have a sporadic origin, whereas only a small per-
centage (5%) is due to familial tumor syndromes [4,5]. Moreover, recent studies exploring the ge-
nomic landscape of PitNETs confirmed and extended earlier studies by reporting that all major 
tumor subtypes studied present a relatively low number of somatic mutations per tumor and that 
there are scarce recurrent mutations, none of which is commonly found across PitNET subtypes [6,7]. 
Overall, these genomic analyses, albeit highly informative and valuable, support the contention that 
mutations and purely genetic alterations alone would not fully explain PitNET tumorigenesis and, 
therefore, that alternative oncogenic events, including epigenetic alterations [8] or miRNAs [9,10], 
should be explored further to understand their actual contribution in this regard. Indeed, the pri-
mary initiating cause of PitNETs development and the possible existence of general and distinctive 
signatures and molecular elements in this heterogeneous pathology is still under debate [4,5,11–14].  
In this scenario, an emerging body of evidence indicates that altered alternative splicing and its 
consequent outcome (i.e., the appearance of abnormal patterns of splicing and therefore, the gener-
ation of aberrant splicing variants), represents a common feature across most tumor pathologies, 
including PitNETs [15–22]. Alternative RNA splicing is a common post-transcriptional mechanism 
that provides a valuable source of biological versatility under physiological circumstances for most 
eukaryotic genes (>95%) [23]. The intracellular machinery that catalyzes and thereby controls the 
process of alternative splicing is the spliceosome, a ribonucleoproteic complex that recognizes spe-
cific sequences that determine the precise localization of the exon-intron junctions [24]. This com-
plex machinery, organized into two systems (the major and the minor spliceosome), is comprised 
by structural/functional ribonucleoproteins that cooperate with splicing factors (SFs), RNA-
dependent ATPase/helicases, and other regulatory proteins [25,26] in a highly dynamic fashion to 
finely regulate the splicing process according to positional principles demarcated by an RNA bind-
ing map to enhance or silence the exon inclusion in the mature RNA [27,28].  
Functional alterations of this splicing-regulatory machinery can compromise the normal splic-
ing process of an ample range of genes, thus originating the appearance of multiple, often aberrant, 
splicing variants, which could be directly associated with the development/progression of tumor 
pathologies [17,18,21,22,29]. Indeed, results from our group have demonstrated that oncogenic 
splicing variants from somatostatin and ghrelin systems (SST5TMD4/5 and In1-ghrelin) are poorly 
expressed in normal tissue but highly expressed in neuroendocrine tumors (NETs), including Pit-
NETs [17–20,30,31], where they increase aggressiveness features. Based on the above, the splicing-
regulatory machinery is becoming an attractive therapeutic target for tumor pathologies [32]. This 
is the case for pladienolide-B, a natural compound that directly targets and binds a key player in 
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the spliceosome, SF3B1, and thereby inhibits spliceosome functions, which in turn appear to medi-
ate the antitumor properties of this promising drug [32–34].  
To date, the expression pattern and putative role of spliceosome components and SFs in the 
development and progression of PitNETs, as well as the potential therapeutic effects of pladi-
enolide-B in PitNET cells, has not been reported. Accordingly, we aimed to comprehensively de-
termine and analyze the expression levels of the spliceosome core components and a selected set of 
relevant SFs in the main PitNETs subtypes, i.e., non-functioning pituitary tumors (NFPTs), somato-
tropinomas (GHomas), corticotropinomas (ACTHomas), and prolactinomas (PRLomas), as com-
pared to normal human pituitary gland samples (NPs). Additionally, we evaluated the potential 
antitumor actions of pladienolide-B in PitNET cells by evaluating key functional parameters (i.e., 
cell proliferation/viability and hormone secretion) in human primary PitNETs cell cultures and two 
models of pituitary cell lines (AtT-20 and GH3). 
2. Results 
In the present study, we analyzed simultaneously the expression levels of 42 components of 
the splicing machinery (12 components of major spliceosome, four components of the minor 
spliceosome, and 26 SFs) in different PitNETs subtypes using a dynamic quantitative real-time PCR 
(qPCR) microfluidic array. Specifically, we evaluated the dysregulations of these spliceosome com-
ponents and SFs in an ample range of human PitNETs samples in comparison with NP-glands. 
Thus, we analyze 88 NFPTs, 48 GHomas, 22 ACTHomas, 7 PRLomas, and 11 NPs (cohort from 
Spain). Additionally, we had the opportunity to evaluate the dysregulation of the splicing machin-
ery in a second cohort of 83 GHomas from Brazil. 
2.1. Dysregulation of Splicing Machinery in NFPTs 
Results from the dynamic qPCR microfluidic custom-made array revealed a marked dysregu-
lation of the expression levels of several components of the splicing machinery in NFPTs compared 
to NPs, wherein nearly half of the elements examined were clearly downregulated (18 out of 42) or 
exhibited a trend to be downregulated in NFPTs (Figure 1A; Figure S1). Specifically, NFPTs showed 
a significant downregulation of four major spliceosome components (RNU4, RNU6, U2AF1 and 
U2AF2), two minor spliceosome components (RNU11 and RNU6ATAC), and 12 splicing factors 
(SFs) (ESRP1, PTBP1, RBM17, RBM45, SND1, SRSF1, SRSF10, SRSF3, SRSF5, SRSF9, TRA2A, and 
TRA2B), while only the SFs MAGOH and SRRM4 were significantly overexpressed (Figure 1A and 
Figure S1). Interestingly, whereas non-supervised hierarchical analysis based on the expression 
pattern of all spliceosome components and SFs analyzed was not able to appropriately separate 
NFPTs from NPs (Figure 1B), Partial Least Squares-Discriminant Analysis (PLS-DA) suggested the 
possibility of discriminating between NFPTs and NPs using the expression pattern of certain 
spliceosome components and SFs (Figure 1C). In line with this, Variable Importance in Projection 
(VIP) score of PLS-DA analysis indicated that SRSF9, SND1, U2AF1, SRRM4, and U2AF2 were the 
components with a higher capacity to discriminate between both populations (Figure 1D).  
Indeed, the expression of SRSF9, SND1, U2AF1, and U2AF2 was decreased while SRRM4 ex-
pression was increased in NFPT samples, and Receiver Operating Characteristic (ROC) curve anal-
yses of these five components corroborated their capacity to significantly discriminate between 
NFPTs and NPs showing an AUC of 0.94, 0.93, 0.93, 0.80, and 0.87, respectively (Figure 1F). Alt-
hough the heatmap generated with the expression of these five components did not completely 
segregate NFPTs and NPs, it separately grouped them by clustering together all NP samples and 
differentiating two subpopulations of NFPTs (P1 and P2) (Figure 1E). Of note, analysis of clinical 
parameters of all NFPTs included in the study revealed that the overexpression of SRRM4 was sig-
nificantly associated with higher chiasmatic compression (Figure 1G). Intriguingly, when the two 
NFPT subpopulations (P1 and P2) were analyzed separately, the five splicing-regulatory elements 
mentioned above showed higher expression levels in P2 compared to P1 NFPTs (Figure S2A). In 
addition, we compared these two subpopulations for their expression of pituitary hormones, classi-
cal receptors related with pituitary pathophysiology and clinical parameters. This revealed that 
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mRNA levels of somatostatin receptor subtypes 1 and 5 (SST1 and SST5) were lower in NFPTs P2 
compared to P1, and those of SST3 were higher in P2, while SST2 and dopamine receptor subtype 2 
(D2: D2T and D2L) levels did not differ between P1 and P2. Finally, gene expression measurement of 
glycoprotein hormone alpha-subunit (CGA) and follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH) beta subunits did not reveal any difference between P2 and P1 (Figure S2B). Like-
wise, no differences were found regarding clinical parameters between both populations of NFPTs 
(Table S1).  
On the other hand, an exhaustive analysis of the first heatmap generated (Figure 1B) showed 
the existence of four different subpopulations of NFPTs (P1–P4; Figure 1B). However, the analysis 
of relevant clinical parameters did not show in this case any significant difference between these 
populations (Table S2). Variable Importance in Projection (VIP) score of PLS-DA analysis unveiled 
certain spliceosome components and SFs with higher capacity to discriminate between the different 
subpopulations of NFPTs and NPs, and the heatmaps generated were able to perfectly discriminate 
between the different subpopulations (P1, P2, P3, or P4) and NPs, segregating them into two perfect 
clusters (Figure S3A–D). Specifically, SND1 and SRSF9 were the components with higher capacity 
to discriminate between NFPTs P1 and NPs; U2AF1, ESRP1, KHDRBS1, and SRRM4 discriminated 
between NFPTs P2 and NPs; RBM17, U2AF1, SND1, and PTBP1 discriminated between NFPTs P3 
and NPs, and; SRSF1 and SND1 discriminate between NFPTs P4 y NPs (Figure S3A–D). In addition, 
we compared the expression of pituitary hormones and classical receptors in these subpopulations, 
and the results revealed a differential mRNA expression pattern of somatostatin receptors (SSTs) 
and D2L but not of pituitary hormones or D2T, between the different subpopulations (Figure S3E). 
At this point, it should be mentioned that a limitation of our study is the low number of NPs sam-
ples included in the analysis. However, it is important to take into account the difficulty to obtain 
this type of sample. 
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Figure 1. Non-functioning pituitary tumors (NFPTs). (A) Individual Fold-Change of each splicing-
regulatory element expression levels in NFPTs compared to normal pituitary glands (NPs). (B) 
Heatmap of the mRNA expression levels of all splicing-regulatory elements measured in the qPCR 
array in NFPTs (n = 88; green color) compared to NPs (n = 11; red color). (C) Principal Components 
Analysis (PCA) of the mRNA expression levels of the splicing-regulatory elements analyzed in the 
same set of samples. (D) Variable Importance in Projection (VIP) Scores top-feature of Partial Least 
Squares Discriminant Analysis (PLS-DA). (E) Heatmap of the splicing-regulatory elements with 
higher VIP score in the same set of samples. (F) mRNA expression levels of splicing-regulatory 
elements with higher VIP score in NFPTs compared to NPs and Receiver Operating Characteristic 
(ROC) curves analyses showing the accuracy of the selected splicing-regulatory elements to 
discriminate between NFPTs and NPs. (G) Correlations between SRRM4 and chiasmatic 
compression in NFPTs. Data represent median ± interquartile range of absolute expression levels 
(copy number) of each transcript adjusted by a normalization factor. Asterisks (* p < 0.05, ** p < 0.01, 
*** p < 0.001) indicate statistically significant differences between groups. 
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2.2. Dysregulation of Splicing Machinery in GHomas 
In somatotropinomas, a clear dysregulation of splicing-regulatory components was also found 
compared to NPs (25 out of 42 elements altered; Figure 2A and Figure S4). Specifically, analysis of 
the first cohort of GHomas (C1; tumors from Spain) showed an overexpression of 6 major spliceo-
some components (SNRNP200, U2AF1, U2AF2, TCERG1, PRPF8, and RBM22), a downregulation of 
one component of the minor spliceosome (RNU11), and 18 SFs significantly overexpressed (CELF1, 
MAGOH, SRRM4, SPFQ, PTBP1, RAVER1, RBM17, RBM3, KHDRBS1, SRSF2, SND1, SRRM1, 
SRSF3, SRSF5, SRSF6, SRSF9, TIA1, and TRA2B) (Figure 2A and Figure S4). A non-supervised hier-
archical analysis using the expression levels of all the splicing-machinery components was able to 
cluster together most NP-samples, although it did not generate a complete, perfect separation of 
GHomas and NPs (Figure 2B), probably due to the low number of NPs in comparison to GHomas. 
In contrast, PLS-DA analysis unveiled a clear segregation between GHomas and NPs based on the 
expression pattern of certain spliceosome components and SFs (Figure 2C). In fact, VIP score of 
PLS-DA analysis indicated that ribonucleoprotein PTB-binding 1 (RAVER1), RNA binding motif 
protein 3 (RBM3), and serine/arginine-rich splicing factor 6 (SRSF6) were the components with 
higher capacity to discriminate between GHomas and NPs (Figure 2D). Moreover, the heatmap 
generated with these three SFs was able to perfectly discriminate between GHomas and NPs, seg-
regating them into two perfect clusters (Figure 2E).  
Indeed, these three SFs (RAVER1, RBM3, and SRSF6) were significantly overexpressed in this 
population of GHoma samples (C1 cohort) and showed ROC curves with an AUC of 0.99, 1, and 
0.98, respectively (Figure 2F). Additionally, we had the opportunity to corroborate these results in 
another, independent, cohort of GHomas from Brazil (cohort-2; C2). In this case, we could confirm 
the overexpression of RAVER1 and RBM3, but not SRSF6, in this cohort of GHomas compared to 
NPs (Figure 2F). Similarly, ROC curves analyses of RAVER1 and RBM3, but not of SRSF6, con-
firmed their capacity to discriminate between NPs with an AUC of 0.77, 0.93, and 0.59, respectively 
(Figure 2F). Finally, the analysis of clinically relevant parameters revealed a clear association be-
tween pre-treatment with somatostatin analogues (SSAs) and higher SRSF6 mRNA expression lev-
els in cohort C1 (Figure 2G). Interestingly, we also found that these high levels of SRSF6 were 
markedly linked to a lower rate of cavernous sinus invasion (Figure 2G). In the same line, high lev-
els of RAVER1 were also associated with less cavernous sinus invasion and also with less extra-
sellar growth (Figure 2G). It is also worth noting that RAVER1 expression levels were also directly 
correlated with the expression of the aberrant splicing variant In1-ghrelin (r: 0.398; p = 0.024) but not 
with native ghrelin (r: 0.133; p = 0.535). 
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Figure 2. Somatotropinomas (GHomas). (A) Individual Fold-Change of each splicing-regulatory el-
ement expression levels in GHomas compared to normal pituitary glands (NPs). (B) Heatmap of the 
mRNA expression levels of all splicing-regulatory elements measured in the qPCR array in 
GHomas (n=48; green color) compared to NPs (n = 11; red color). (C) Principal Components Analy-
sis (PCA) of the mRNA expression levels of the splicing-regulatory elements analyzed in the same 
set of samples. (D) Variable Importance in Projection (VIP) Scores top-feature of Partial Least 
Squares Discriminant Analysis (PLS-DA). (E) Heatmap of the splicing-regulatory elements with 
higher VIP score in the same set of samples. (F) mRNA expression levels of splicing-regulatory ele-
ments with higher VIP score in GHomas from cohorts 1 (C1; n = 48) and 2 (C2; n = 83) compared to 
NPs (n = 11) and Receiver Operating Characteristic (ROC) curves analyses showing the accuracy of 
the selected splicing-regulatory elements to discriminate between both cohorts of GHomas and NPs. 
(G) Correlations between SRSF6 and RAVER1 expression and clinical parameters. Data represent 
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median ± interquartile range of absolute expression levels (copy number) of each transcript adjusted 
by a normalization factor. Asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001) indicate statistically signifi-
cant differences between groups. 
2.3. Dysregulation of Splicing Machinery in ACTHomas 
In corticotropinomas, qPCR array revealed a significantly dysregulation of 12 splicing machin-
ery components, three components of major spliceosome (upregulation of RNU2 and SNRNP200, 
and downregulation of U2AF2), one component of the minor spliceosome (upregulation of 
RNU12), and eight SFs (upregulation of MAGOH, NOVA1, SPFQ, KHDRBS1, SRSF2, SNW1, 
TRA2B, and downregulation of ESRP1) (Figure 3A and Figure S5). Non-supervised hierarchical 
analysis of all splicing machinery components analyzed did not generate a clustering capable to 
discriminate between ACTHomas and NPs (Figure 3B), also probably due to the low number of 
NPs in comparison to ACTHomas. Conversely, PLS-DA analysis showed a clear separation be-
tween ACTHomas and NPs (Figure 3C), and the VIP score of PLS-DA analysis revealed that the 
pattern of two SFs with the highest score (MAGOH and KHDRBS1) was able to discriminate be-
tween ACTHomas and NPs (Figure 3D). In line with this, the heatmap generated with these two 
SFs was able to discriminate between ACTHomas and NPs, segregating them into two perfect clus-
ters (Figure 3E). Indeed, these two SFs (MAGOH and KHDRBS1) were markedly overexpressed in 
ACTHomas, and ROC curves of these SFs corroborated their capacity to discriminate between AC-
THomas and NPs with an AUC of 1 and 0.97, respectively (p < 0.0001; Figure 3F).  
Additionally, we evaluated the association of clinically relevant parameters with the expres-
sion of these two key SFs in this cohort of ACTHomas (Figure 3G). Specifically, we found that ex-
pression of MAGOH was higher in women than in men, and that MAGOH overexpression was 
associated with less chiasmatic compression. In fact, tumor samples showing chiasmatic compres-
sion were all men with low MAGOH expression levels (with the exception of one woman) (Figure 3F). 
Furthermore, ACTHomas with higher MAGOH expression levels presented higher curation rate 
(Figure 3G). Interestingly, MAGOH mRNA levels were directly correlated with those for the aber-
rant splicing variant SST5TMD4 (truncated somatostatin receptor type 5 with 4 transmembrane 
domains) (r: 0.491; p = 0.033) but not with the canonical receptor SST5 (r: 0.146; p = 0.552).  
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Figure 3. Corticotropinomas (ACTHomas). (A) Individual Fold-Change of each splicing-regulatory 
element expression levels in ACTHomas compared to normal pituitary glands (NPs). (B) Heatmap 
of the mRNA expression levels of all splicing-regulatory elements measured in the qPCR array in 
ACTHomas (n = 22; green color) compared to NPs (n = 10; red color). (C) Principal Components 
Analysis (PCA) of the mRNA expression levels of the splicing-regulatory elements analyzed in the 
same set of samples. (D) Variable Importance in Projection (VIP) Scores top-feature of Partial Least 
Squares Discriminant Analysis (PLS-DA). (E) Heatmap of the splicing-regulatory elements with 
higher VIP score in the same set of samples. (F) mRNA expression levels of splicing-regulatory 
elements with higher VIP score in ACTHomas compared to NPs and Receiver Operation 
Characteristic (ROC) curves analyses showing the accuracy of the selected splicing-regulatory 
elements to discriminate between ACTHomas and NPs. (G) Correlations between MAGOH and 
clinical parameters. Data represent median ± interquartile range of absolute expression levels (copy 
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number) of each transcript adjusted by a normalization factor. Asterisks (* p < 0.05, ** p < 0.01, *** p < 
0.001) indicate statistically significant differences between groups. 
2.4. Dysregulation of Splicing Machinery in PRLomas 
PRLomas also exhibited a clearly dysregulated expression pattern of spliceosomal components 
(12 out of 42) compared to NPs (Figure 4A and Figure S6), with a clear overexpression of three ma-
jor spliceosome components (PRPF40A, PRPF8, and RBM22), a downregulation of one minor 
spliceosome component (RNU11), and an overexpression of eight SFs (MAGOH, SRRM4, PTBP1, 
RAVER1, RBM3, KHDRSB1, SRSF2, and SRSF6) (Figure 4A and Figure S6). Non-supervised hierar-
chical analysis did not generate a perfect clustering between PRLomas and NPs (Figure 4B). How-
ever, PLS-DA analysis neatly revealed a different expression pattern between PRLomas and NPs 
(Figure 4C), and VIP score analysis identified three components with high capacity to discriminate 
between both populations (RAVER1, MAGOH, and RNU11) (Figure 4D). Indeed, the heatmap gen-
erated with the expression of these three components produced an almost complete clustering of 
PRLomas and NPs (all except for one NP sample) (Figure 4E). Thus, RNU11 was found to be signif-
icantly downregulated, and RAVER1 and MAGOH were overexpressed in PRLoma samples com-
pared to NPs, showing ROC curves with an AUC of 0.97, 1, and 0.93, respectively (Figure 4F). In 
this tumor type, no relevant association were found with clinical parameters or splice variants. 
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Figure 4. Prolactinomas (PRLomas). (A) Individual Fold-Change of each splicing-regulatory ele-
ment expression levels in PRLomas compared to normal pituitary glands (NPs). (B) Heatmap of the 
mRNA expression levels of all splicing-regulatory elements measured in the qPCR array in PRLo-
mas (n = 7; green color) compared to NPs (n = 11; red color). (C) Principal Components Analysis 
(PCA) of the mRNA expression levels of the splicing-regulatory elements analyzed in the same set 
of samples. (D) Variable Importance in Projection (VIP) Scores top-feature of Partial Least Squares 
Discriminant Analysis (PLS-DA). (E) Heatmap of the splicing-regulatory elements with higher VIP 
score in the same set of samples. (F) mRNA expression levels of splicing-regulatory elements with 
higher VIP score in PRLomas compared to NPs and Receiver Operating Characteristic (ROC) curves 
analyses showing the accuracy of the selected splicing-regulatory elements to discriminate between 
PRLomas and NPs. Data represent median ± interquartile range of absolute expression levels (copy 
number) of each transcript adjusted by a normalization factor. Asterisks (* p < 0.05; ** p < 0.01, 
*** p < 0.001) indicate statistically significant differences between groups. 
  
Cancers 2019, 11, 1439 12 of 25 
2.5. Similar Dysregulation of Specific Splicing Machinery Components in all PitNET Subtypes 
A fold-change representation of the splicing machinery alterations in all PitNETs subtypes 
analyzed revealed a common fingerprint between all of them (Figure S7A). Specifically, we found a 
common downregulation of two minor spliceosome components (RNU11 and RNU6ATAC) and 
one SF (SRSF1) and also a common overexpression of one SF (SRRM4). However, these changes did 
not reach statistical significance in all subtypes (Figure S7B). Interestingly, SRSF1 mRNA levels 
were directly correlated with the aberrant splicing variant SST5TMD4 in NFPTs (r: 0.425; p = 0.049), 
GHomas (r: 0.532; p = 0.002), and ACTHomas (r: 0.509; p = 0.026). In contrast, this SF did not corre-
late with the canonical receptor SST5 in GHomas (r: −0.037; p = 0.862) or ACTHomas (r: 0.140; p = 
0.567) but directly correlated with SST5 in NFPTs (r: 0.329; p = 0.004). Additionally, expression levels 
of SST5TMD4, but not SST5, were also directly associated with those of RNU11 (r: 0.392; p = 0.026), 
RNU4ATAC (r: 0.422; p = 0.016), and RNU6ATAC (r: 0.450; p = 0.010) in GHomas. 
2.6. Effect of Pladienolide-B Treatment in PitNETs Cells 
Dose-response experiments using pladienolide-B in two representative pituitary cell lines, 
AtT-20 corticotrophs and GH3 somatotrophs, at different times of incubation showed that lower 
doses of pladienolide-B (10−9 and 10−11 M) did not alter cell proliferation at any of the times tested 
(Figure 5A). In contrast, the 10−7 M dose of pladienolide-B markedly decreased cell proliferation at 
24, 48 and 72h in both cell lines (Figure 5A). We also evaluated the mRNA and protein expression 
levels of SF3B1 (the target of pladienolide-B) in both cell lines and the results showed that SF3B1 
was highly expressed in AtT-20 than in GH3 cells (Figure 5B). Interestingly, although both cell lines 
showed different expression levels of SF3B1, the effect of pladienolide-B in cell proliferation was 
very similar in both cell lines. In the same line, treatment with pladienolide-B at 10-9 and 10-11 M did 
not modify cell viability in primary pituitary cell cultures of GHomas, ACTHomas, and NFPTs, but 
treatment with 10−7 M clearly reduced cell viability after 48 and 72 h of incubation in GHomas and 
after 72h in ACTHomas and NFPTs (Figure 5C). Based on these results, the 10-7 M dose was used to 
evaluate the direct effect of this compound on hormone secretion. The results revealed that treat-
ment with pladienolide-B reduced GH, but not chromogranin-A, secretion after the 24h incubation 
in GHomas and NFPTs, respectively (Figure 5D). 
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Figure 5. Functional assays in response to pladienolide-B in pituitary cell lines and pituitary 
neuroendocrine tumors (PitNETs) primary cell cultures. (A) Dose-response experiments of cell 
proliferation in response to pladienolide-B at 10−7, 10−9, and 10−11 M in GH3 and AtT20 cells (n = 4), 
measured by Alamar-blue reduction. (B) mRNA and protein levels of SF3B1 in GH3 and AtT-20 
cells (n = 4), measured by qPCR and western blotting. (C) Dose-response experiments of cell 
viability in response to pladienolide-B in non-functioning PitNETs (NFPTs; n = 5), 
somatotropinomas (GHomas; n = 3), and corticotropinomas (ACTHomas; n = 3), measured by 
Alamar-blue reduction. (D) Effect of pladienolide-B in growth hormone (GH) and chromogranin-A 
secretion from GHomas and NFPTs, respectively, determined by commercial ELISA (Enzyme-
Linked ImmunoSorbent Assay) kit (n = 2). Data are expressed as percent of vehicle-treated controls 
(set at 100%) within experiment. Values represent the mean ± standard error of the mean (SEM). 
Asterisks (* p < 0.05; ** p < 0.01; *** p < 0.001) indicate statistically significant differences. In cases 
where less than three experiments were performed, no significance tests were performed. 
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3. Discussion 
Evidence gathered over the last years indicates that tumor pathologies, including neuroendo-
crine tumors (NETs) share as a common feature the altered expression of functionally and patho-
logically relevant splicing variants of diverse molecules, from membrane receptors to key signaling 
enzymes (DLK1, GHRHR, IGF1R, EGFR, CSH2, or PTEN) [35–38]. Actually, results from our group 
led to the identification of previously unrecognized aberrant splicing variants from somatostatin 
and ghrelin systems (SST5TMD4/5 and In1-ghrelin) and demonstrated that these variants are over-
expressed in tumors and can contribute to their oncogenesis, increasing aggressiveness and malig-
nant features in different tumor types, including PitNETs [17–22,31,39,40]. To ascertain the potential 
mechanisms underlying the genesis of these tumor-related abnormal splicing events, we hypothe-
sized that they could be linked to alterations in the machinery responsible for this process, i.e., the 
spliceosome and its associated SFs. In line with this notion, mutations and other functional defects 
in certain spliceosome components have been reported to cause diverse pathologies, including can-
cer [41]. Accordingly, the present study was devised to determine the pattern of expression of the 
splicing machinery in the main types of PitNETs and to assess the potential existence of specific 
alterations in spliceosome components and SFs associated to each pituitary tumor type, which may 
serve as future tools to guide the diagnostic/prognostic of these tumors and could provide novel 
actionable therapeutic targets. Indeed, results from this study demonstrate, for first time, that the 
splicing machinery (spliceosome and SFs) seems to be distinctly dysregulated in all PitNETs sub-
types compared to NP glands, and that its modulation with a specific drug targeting SF3B1, a key 
player in the spliceosome function, decreases aggressiveness features in PitNET cells. 
One of the main findings of this study is the discovery that the spliceosome machinery is 
dysregulated in a tumor subtype-dependent manner, where NFPTs, GHomas, ACTHomas, and 
PRLomas exhibit a differentially altered pattern of expression. Of particular interest are the results 
found in NFPTs, which displayed a profound downregulation of most of the components analyzed, 
in striking contrast with the alterations observed in functioning PitNETs (GHomas, ACTHomas, 
and PRLomas), wherein many components are overexpressed. In line with this, previous results 
have demonstrated that NFPTs typically display a distinct behavior and different expression pat-
tern of relevant components involved in pituitary cell function, such as somatostatin receptors, in 
comparison with functioning PitNETs and normal tissue [42–45]. Interestingly, our results showed 
that the expression levels of SRSF9, SND1, U2AF1, U2AF2 and SRRM4 were able to discriminate, 
although not perfectly, between NFPTs and NP tissues. The absence of a perfect discrimination 
between both populations could be, in part, due to the well-known intrinsic heterogeneous nature 
of NFPTs [46], which was also evident in our bioinformatic analyses showing a clear differentiation 
between the four subpopulations of NFPTs (P1–P4) represented in the first heatmap generated 
(Figure 1B) and also between the two subpopulations of NFPTs (P1 and P2) represented in the sec-
ond heatmap (Figure 1E), in terms of expression of splicing machinery components and some path-
ophysiologically relevant receptors (SST1–5 and D2). Nonetheless, the clear alteration of these 
spliceosome components found in our global cohort of NFPTs has also been observed in other tu-
mor pathologies. Specifically, SRSF9 and SND1 have been found overexpressed in several tumor 
pathologies, such as breast cancer, bladder cancer, glioblastoma, melanoma, or hepatocellular car-
cinoma, where they have been associated with an increase in cell proliferation, invasion and poor 
prognosis [47–51]. The fact that these SFs were downregulated in NFPTs, in contrast with the over-
expression observed in other pathologies, may be likely reflect the complexity, heterogeneity, and 
limited functional deployment of these tumors. In addition, U2AF1 is an important component of 
the major spliceosome that has been found frequently mutated and associated to the generation of 
particular splicing patterns in several pathologies, including the production of oncogenic splicing 
variants in cancer [52,53]. In this sense, our data unveiled a clear downregulation of U2AF1 in 
NFPTs compared to NPs, which might suggest that not only the mutational profile but also the 
expression pattern could be involved in the malignant behavior of tumor pathologies including 
NFPTs. Consistently, we found in NFPTs a downregulation of U2AF2, an SF that heterodimerizes 
with U2AF1. Although the relationship of U2AF2 with tumorigenesis is poorly studied, certain 
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reports have demonstrated cancer-associated mutations in this SF [54], and it has also been found 
upregulated in lung cancer and highly metastatic hepatocellular carcinoma [55]. Remarkably, we 
found that SRRM4 was the only SF significantly upregulated in NFPTs, which was also associated 
with higher chiasmatic compression. These results compare nicely with the overexpression of 
SRRM4 reported in small cell lung cancers and in neuroendocrine prostate cancers, where SRRM4 
was also correlated with poor patient survival [56,57].  
On the other hand, in GHomas, a profound overexpression of three SFs—ribonucleoprotein 
PTB-binding 1 (RAVER1), RNA binding motif protein 3 (RBM3), and serine/arginine-rich splicing 
factor 6 (SRSF6)—was observed, which provided an expression pattern able to discriminate neatly 
between GHomas and NPs. Importantly, the altered expression pattern of RAVER1 and RBM3 was 
corroborated in a second, independent cohort of GHomas from Brazil. Previous results from our 
group have revealed that the alteration of these spliceosome components could be associated to the 
development of different pathological conditions. Indeed, dysregulation of RAVER1 and RBM3 has 
been recently related with the development of non-alcoholic fatty liver disease [58], while RAVER1 
has been found to be dysregulated in patients with cardiovascular disease at higher risk of type-2 
diabetes development [59]. Most importantly, additional evidence suggests that alterations in the 
expression level of RBM3 could be associated with advanced pathological tumor stages in lung 
carcinoma or with aggressive features in esophageal, colorectal or breast cancer [60–63], which rein-
forces the crucial role of this factor in tumor pathologies. In the case of SRSF6, the results of the first 
cohort analyzed demonstrated that the overexpression of this SF was associated with lower cavern-
ous sinus invasion and with SSAs pre-treatment. Interestingly, and in line with the previous obser-
vation, the difference observed in the expression levels of SRSF6 between both cohorts of GHomas 
(i.e., upregulated in the Spanish cohort and no change in the Brazilian cohort) could be due to the 
fact that the patients from Spain, but not from Brazil, were pre-treated with somatostatin analogues 
before surgery, which has been shown to alter the expression pattern of key receptors in pituitary 
tumor samples [64]. Indeed, we also found a significant association between the pre-treatment with 
SSAs and higher SRSF6 mRNA expression levels in C1. Therefore, although with all required cau-
tion, these results invite us to speculate that perhaps there is a link between pre-treatment with 
somatostatin analogues and some beneficial effects for patient harboring GHomas in regard to 
some clinical symptoms such as cavernous sinus invasion, which could involve the modulation of 
splicing-machinery elements (i.e., upregulation of SRSF6). 
In ACTHomas, our results demonstrated that the altered expression of only two SFs, MAGOH 
and KHDRBS1, was sufficient to fully discriminate ACTHomas from NPs. These SFs were marked-
ly upregulated in ACTHomas, which is in accordance with the increased expression of KHDRBS1 
found in gastric cancer, epithelial ovarian cancer or sacral chordomas, wherein its presence was 
associated with poor prognosis and aggressive characteristics [65,66]. Likewise, MAGOH has been 
shown to be differentially expressed in breast cancer, where it served, together with other RNA 
processing factors, to develop a robust stratification of breast cancer subtypes [67]. However, the 
presence and potential role of KHDRBS1 and MAGOH in PitNETs or NPs has not hitherto been 
reported. In this sense, in our cohort of ACTHomas, lower levels of MAGOH were found in men, 
who showed more chiasmatic compression, while higher MAGOH expression levels were associat-
ed with higher curation rate. Although these results might appear contradictory, and their potential 
biological significance is still far from being elucidated, our findings, together with the previous 
observations, prompt us to suggest that a dysbalance in some elements of the splicing machinery 
could be functionally related to specific pathophysiologic features of PitNETs, as it is emergently 
clear in other types of tumors and cancers.  
Our data in PRLomas also revealed a clear dysregulation of the splicing-machinery compo-
nents. Moreover, the altered expression of several splicing-regulatory elements was able to distin-
guish, although not in a perfect manner, between PRLomas and NPs. The lower refinement of these 
models as compared to the results with other PitNET subtypes might probably be associated to the 
low number of PRLomas analyzed in this study, owing to the difficulty to have access to this type 
of samples, since dopamine agonist treatment is often highly successful in patients with PRLomas.  
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Together with the identification of clearly distinct, tumor type–dependent dysregulations of 
the components of the splicing machinery, it is worth noting that we also pinpointed a common 
pattern of dysregulation of two minor spliceosome components (RNU11 and RNU6ATAC) and two 
SFs (SRSF1 and SRRM4) in most PitNETs, irrespective of their subtype, an observation that might 
be patho-physiologically relevant and thus bear future clinical potential. In particular, SRSF1 has 
been described to interact with many different proteins to regulate several cellular functions, in-
cluding splicing, and has been found overexpressed in several types of cancer (breast and lung 
cancer), where it is considered a proto-oncogene [68]. Indeed, our results demonstrated that SRSF1 
positively correlated with the oncogenic splicing variant SST5TMD4 in NFPTs, GHomas, and AC-
THomas, and also that RNU11, and RNU6ATAC correlated with SST5TMD4 in GHomas. The fact 
that these spliceosome components are similarly dysregulated in all PitNETs and that these com-
ponents also correlated with aberrant splicing variants, despite the high heterogeneity of these tu-
mors, invite us to speculate about the possible existence of previously unrecognized common driver 
alterations in pituitary tumorigenesis, which would pave the way toward the identification of nov-
el, common therapeutic targets based on the dysregulations of these key elements. However, fur-
ther studies should be conducted to test this hypothesis. 
Finally, and in line with to the previous results, our study also provides an initial, unprece-
dented proof-of-concept on the suitability of splicing dysregulation as a novel potential target for 
PitNET treatment by demonstrating that the pharmacological disruption of the splicing process 
with specific drugs may have antitumor effects in these neoplasms. In particular, we tested the di-
rect in vitro effect of pladienolide-B in different PitNETs subtypes and pituitary cell lines. This 
compound is able to directly target a key component involved in the assembly of the spliceosome 
SF3B1 [69], leading to the reduction of its activity [70]. Several reports have associated pladienolide-
B with antitumor properties in different cancer types [33,71–73], but its role in PitNETs was still 
unknown. For these reasons, we used this compound due to its capacity to naturally disrupt the 
splicing process targeting SF3B1. Thus, our results demonstrate for the first time that treatment 
with pladienolide-B inhibits cell viability/proliferation in all PitNETs subtypes tested and in AtT-20 
and GH3 cell lines, which compares well with the reduction on cell viability and colony formation 
observed in HeLa cells [33] and with recent data from our group demonstrating that pladienolide-B 
reduced proliferation, migration and tumorspheres-formation in prostate cancer cells [33]. Interest-
ingly, NFPTs were less sensitive to the effect of pladienolide-B compared to GHomas or ACTHom-
as, which is in line with previous observations in response to other pharmacological treatments in 
NFPTs [42,43,74]. Notably, pladienolide-B was also able to reduce GH secretion after 24 h of incuba-
tion, a relevant result since tumor hypersecretion is linked to most of the symptoms caused by 
GHomas. 
4. Materials and Methods  
4.1. Drugs and Reagents 
All reagents and drugs used in this study were purchased from Sigma-Aldrich (Madrid, Spain) 
or Fluidigm (San Francisco, CA, USA) unless otherwise specified. Pladienolide-B was obtained 
from Santa Cruz Biotechnology (Heidelberg, Germany). 
4.2. Patients, Samples, and Primary Cell Cultures 
Human PitNETs samples were collected during transsphenoidal surgery from 171 patients 
from Spain (88 NFPTs (mean age: 58 (20–83); 40% women), 48 GHomas (mean age: 43 (21–64); 59 % 
women; Cohort 1; C1), 22 ACTHomas (mean age: 40 (18–61); 82% women), and seven PRLomas 
(mean age: 43 (28–74); 29% women). Moreover, a second cohort of 83 GHomas from Brazil (Cohort 
2; C2) was obtained. Additionally, 11 normal pituitary glands (NP) (mean age: 61 (44–85); 50% 
women) were obtained during autopsies. Each pituitary sample subtype was confirmed by expert 
anatomo-pathologists and by the molecular screening using qPCR, as previously described 
[17,42,75,76]. In all cases, samples were immediately placed in sterile cold medium (S-MEM, Gibco, 
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Madrid, Spain; supplemented with 0.1% bovine serum albumin (BSA), 0.01% L-glutamine, 1% anti-
biotic-antimycotic solution, and 2.5% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
after surgery and rapidly frozen and stored at –80 °C until extraction for total RNA. In a second set 
of experiments, PitNETs samples placed in sterile cold medium after surgery were dispersed into 
single cells following the methods and reagents previously described [42,76]. This study was carried out 
within a project approved on 27th November 2013 by our Hospital Research Ethics Committee 
(reference 1992), was conducted in accordance with ethical standards of the Helsinki Declaration of 
the World Medical Association, and written informed consent was obtained from each patient. 
4.3. Cell Lines and Culturing 
The mouse corticotrope pituitary derived cell line AtT-20/D16v-F2 (ATCC® CRL-1795™) and 
the rat somatotrope pituitary derived cell line GH3 (ATCC® CCL-82.1™) were used in the present 
study. Both cell lines were checked for mycoplasma contamination by PCR [77], cultured in Dul-
becco’s Modified Eagle’s Medium (DMEM) complemented with 10% fetal bovine serum (FBS), 100 
U/mL penicillin/streptomycin, 0.024 M of HEPES, and maintained at 37 °C and 5% CO2, under ster-
ile conditions. 
4.4. RNA Extraction, Quantification and Reverse Transcription 
Total RNA from fresh tissue samples was isolated using AllPrep DNA/RNA/Protein Mini Kit 
followed by DNase treatment using RNase-Free DNase Set (Qiagen, Limburg, Netherlands). Total 
RNA concentration and purity was assessed using Nanodrop 2000 spectrophotometer (Thermo 
Fisher, Waltham, MA, USA), and retro-transcribed using random hexamer primers with the First 
Strand Synthesis Kit (Thermo Fisher). 
4.5. Analysis of Splicing Machinery Components by a Customized qPCR Dynamic Array 
As previously described [58,59], a 48.48 Dynamic Array based on microfluidic technology (Flu-
idigim) was used to determine the expression levels of 48 transcripts in 48 PitNETs samples, simul-
taneously. The specific set of primers used in this study has been previously reported by our group 
[58,59], and include components of the major (n = 12) and minor (n = 4) spliceosome, associated SFs 
(n = 26), and three reference genes (beta-actin (ACTB), hypoxanthine phosphoribosyltransferase 1 
(HPRT1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)), used for the normalization 
of gene expression levels). To control for variations in the amount of RNA used and the efficiency 
of the reverse-transcription reaction, the expression level of each transcript was adjusted by a nor-
malization factor (NF) calculated with the mRNA expression levels of ACTB, HPRT1, and GAPDH 
using Genorm 3.3 method [78]. 
We performed a preamplification, exonuclease treatment, and the qPCR dynamic array follow-
ing the manufacturer’s instructions. Thus, 12.5ng of cDNA of each sample were pre-amplified using 
1μL of PreAmp Master Mix (Fluidigm) and 0.5μL of all primers mix (500nM) in a T100 Thermal-
cycler (BioRad, Hercules, CA, USA) using the following program: 1) 2 min at 95 °C; 2) 15 sec at 94 
°C, and 4 min at 60 °C (14 cycles). Then, samples were treated with 2μL of 4U/μL Exonuclease I 
solution (New England BioLabs, Ipswich, MA, USA) following manufacturer’s instructions. Sam-
ples were diluted with 18μL of TE Buffer (Thermo Scientific), and 2.7μL were mixed with 3μL of 
EvaGreen Supermix (Bio-Rad) and 0.3μL of DNA Binding Dye Sample Loading Reagent (Flu-
idigm). Primers were diluted to 5μM with 2X Assay Loading Reagent (Fluidigm). Control line fluid 
was charged in the chip and Prime script program was run into the IFC controller MX (Fluidigm). 
Finally, 5μL of each primer and 5μL of each sample were pipetted into their respective inlets on the 
chip, and the Load Mix script in the IFC controller software was run. After this program, the qPCR 
was run using Biomark System (Fluidigm) with the following thermal profile: 1) 1 min at 95 °C; 2) 
35 cycles of denaturing (5 sec at 95 °C) and annealing/extension (20 sec at 60 °C); and 3) a last cycle 
where final products were subjected to graded temperature–dependent dissociation (60 °C to 95 °C, 
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increasing 1 °C/3 sec). Results were processed with Real-Time PCR Analysis Software 3.0 (Flu-
idigm). 
4.6. RNA Isolation, Reverse Transcription, and Analysis of Gene Expression Levels by qPCR 
Details of RNA extraction, quantification, reverse-transcription (RT) and qPCR using specific 
primers included in this study (splicing factor 3b subunit 1 (SF3B1), glycoprotein hormone alpha 
polypeptide (CGA), follicle stimulating hormone (FSH), luteinizing hormone (LH), somatostatin 
receptors (SSTs), and D2) have been previously reported elsewhere by our group [34,78]. It should 
be noted that, as previously reported and based on the stringent criteria to maximize specificity and 
efficiency, the qPCR technique, as applied, can be used to accurately quantify copy numbers for all 
human transcripts included in this study [79]. The expression level of SF3B1 in PitNETs cell lines 
(AtT-20 and GH3) was adjusted by a normalization factor  calculated with the mRNA expression 
levels of ACTB, HPRT1, and GAPDH using Genorm 3.3 method [78]. However, due to the limited 
amount of sample available, we were only able to analyze by conventional qPCR one reference 
gene in the case of primary PitNETs cell cultures. In this sense, we evaluated the stability of the 
expression of three reference genes ACTB, HPRT1, and GAPDH in all samples using Genorm 3.3 
method [80], a comprehensive tool that integrates the currently available major computational pro-
grams and found ACTB to be the most stable. Taking this into account, the expression values of 
CGA, FSH, LH, SSTs, and D2 transcripts were normalized to ACTB mRNA levels. 
4.7. Measurement of Cell Proliferation/Viability 
As previously reported [17,42,75], 10,000 cells per well (for PitNET cells) and 6000 cells per 
well (for cell lines) were plated in 96-well plates to measure cell proliferation/viability every 24h 
until 72h using Alamar-blue reagent (Invitrogen, Madrid, Spain). Pladienolide-B was daily re-
freshed after each measurement, and cell proliferation/viability was evaluated using Flex-Station III 
System (Molecular Devices, Sunnyvale, CA, USA). 
4.8. Measurement of Hormone Secretion 
We plated 150,000–200,000 cells per well in 24-well plates in serum-containing media. GH-
secreting PitNETs cells were used to analyze the effect of pladienolide-B on GH secretion after 24h 
of incubation in serum-free media. GH and chromogranin-A were measured using human com-
mercial ELISA kit (reference numbers: EIA-3552 and EIA-4937, respectively; DRG, Mountainside, 
NJ), according to the manufacturer’s instructions. 
4.9. Measurement of SF3B1 by Western Blotting 
Briefly, 500,000 cells/well were cultured in 6-well plates and incubated during 48 h. After this 
time, proteins were extracted, separated by sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) and transferred to nitrocellulose membranes (Millipore, Darmstadt, Germany), as 
previously reported [17]. Then, blocked membranes were incubated with the primary antibody to 
detect SF3B1 (Abcam, Cambridge, UK; ab172634) and with appropriate secondary antibody (anti-
rabbit antibody from Cell Signaling, Danvers, MA, USA), and developed using an enhanced chemi-
luminescence detection system (GE Healthcare, Barcelona, Spain) with dyed molecular weight 
markers. A densitometric analysis of the bands was carried out with ImageJ software. Proteins were 
normalized using total protein loading (ponceau staining). 
4.10. Statistical Analysis 
All data were evaluated for heterogeneity of variance using the Kolmogorov-Smirnov test. Sta-
tistical differences from qPCR dynamic array results were evaluated by unpaired nonparametric 
Mann-Whitney test and data were expressed as mean ± interquartile range. As previously reported 
[18,31], ROC curves were used as a tool to measure how well the expression of splicing machinery 
components could discriminate between different diagnostic groups. Statistical analysis of ROC 
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curves was performed by calculating the Area Under the Curve (AUC) of each component and 
comparing them with the AUC of the reference line using Student’s t-test. Heatmaps and clustering 
analysis were performed using MetaboAnalyst 3.0 [81]. In this sense, the splicing machinery com-
ponents that discriminate between PitNETs and NPs were selected following two main criteria in 
all cases. First, the VIP score must be higher or equal than 1.5, this value being considered as a sig-
nificant value in this type of analysis. Second, and in order to perform a screening of the selected 
splicing machinery components by the first criteria, we chose only those that are enough to get the 
best hierarchical clustering in the heatmaps. Moreover, PLS-DA analysis is a statistical method close 
to principal components analysis (PCA) that changes the maximum variance finding by a linear 
regression model in a different dimension showing the best elements to discriminate between dif-
ferent experimental groups, in this case, normal pituitary glands and PitNETs. The splicing statisti-
cal analyses from functional assays were assessed by paired parametric t-test or one-way ANOVA 
test followed by Dunnett’s test for multiple comparisons, and data were expressed as mean ± SEM. 
Clinical correlations were assessed by unpaired nonparametric Mann-Whitney test or the Spearman 
test. As previously reported, to normalize values within each treatment and minimize intragroup 
variations in the different in vitro experiments (i.e., different age of the tissue donor or metabolic 
environment), the values obtained were compared with vehicle-treated controls (set at 100%). All 
experiments were performed in a minimum of three different primary pituitary cultures from dif-
ferent patients (three or four replicates per treatment per experiment), unless otherwise specified. P 
values ≤ 0.05 were considered statistically significant. A trend for significance was indicated when 
p-values ranged between >0.05 and <0.1. All statistical analyses were performed using GraphPad 
Prism 6 (GraphPad Software, La Jolla, CA, USA) or SPSS version 24.0 (SPSS, Inc., Chicago, IL, USA). 
5. Conclusions 
In summary, the present results provide novel, compelling evidence to propose that the splic-
ing machinery is severely and distinctly dysregulated in the main subtypes of PitNETs compared to 
NPs and identified unique fingerprints of spliceosome components in each PitNETs subtype that 
can accurately discriminate between normal and tumor pituitary tissues. Furthermore, we also 
found several components, including SFs (SRSF1 and SRRM4) and specially two minor spliceosome 
components (RNU11 and RNU6ATAC), commonly dysregulated in all PitNET subtypes, which 
positively correlated with oncogenic splicing variants and could represent novel, more general 
therapeutic targets in these pathologies. These discoveries open a new window to investigate the 
plausible contribution of splicing dysregulation and its subsequent outcomes to pituitary tumor-
igenesis, and to assess the potential value of specific splicing machinery components as novel diag-
nostic/prognostic tools in these pathologies. Furthermore, our study unveils splicing, particularly 
SF3B1, as a novel actionable therapeutic point that can be targeted by Pladienolide-B to combat 
PitNETs. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: mRNA 
expression levels of all spliceosome components and splicing factors measured in NFPTs compared to NPs 
using the qPCR array, Figure S2: Non-functioning pituitary tumors (NFPTs). (A) mRNA expression levels of 
SRSF9, SND1, U2AF1, SRRM4 and U2AF2 in the two population of NFPTs (P1 and P2) observed in the 
heatmap. (B) mRNA expression levels of classical hormones (CGA, FSH and LH) and somatostatin and 
dopamine receptors (SST1–5 and D2) in the two population of NFPTs observed in the heatmap, Figure S3: Non-
functioning pituitary tumors (NFPTs). (A–D) Heatmaps of the splicing-regulatory elements with higher VIP 
score in the different populations of NFPTs (P1–P4) analyzed. (E) mRNA expression levels of classical 
hormones (CGA, FSH and LH) and somatostatin and dopamine receptors (SST1–5 and D2) in the four 
populations of NFPTs observed in the first heatmap; Figure S4: Somatotropinomas (GHomas). mRNA 
expression levels of all spliceosome components and splicing factors measured in GHomas compared to NPs 
using the qPCR array; Figure S5: Corticotropinomas (ACTHomas). mRNA expression levels of all spliceosome 
components and splicing factors measured in ACTHomas compared to NPs using the qPCR array; Figure S6: 
Prolactinomas (PRLomas). mRNA expression levels of all spliceosome components and splicing factors 
measured in PRLomas compared to NPs using the qPCR array; Figure S7: (A) Individual Fold-Change of 
spliceosome machinery expression levels showing the common dysregulated components (blue and yellow 
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colors) in all PitNETs subtypes compared to NPs. (B) mRNA expression levels of spliceosome components and 
the splicing factor commonly dysregulated in NFPTs, GHomas, ACTHomas, and PRLomas, respectively; Table 
S1: Results from Chi-square test of clinical parameters between P1 and P2 of NFPTs derived from the second 
heatmap; Table S2: Results from Chi-square test of clinical parameters between P1, P2, P3 and P4 of NFPTs 
derived from the first heatmap (cutting the dendogram at second highest height). 
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